About Protein mab-21-like 4
Protein mab-21-like 4 (MAB21L4) is a protein
from Homo sapiens identified by UniProt accession
Q08AI8, 447 residues long.
MolForge cross-references it against 0 known binders and
31 disease associations.
Target properties
| Protein name | Protein mab-21-like 4 |
| UniProt accession | Q08AI8 |
| Gene | MAB21L4 |
| Organism | Homo sapiens |
| Length | 447 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (31)
Diseases linked to this target (Open Targets).
- vital capacity · score 0.32
- BMI-adjusted hip circumference · score 0.32
- body height · score 0.30
- urinary metabolite measurement · score 0.24
- blood metabolite measurement · score 0.24
- forced expiratory volume · score 0.16
- joint hypermobility measurement · score 0.11
- FEV/FVC ratio · score 0.08
- sex hormone-binding globulin measurement · score 0.06
- esophageal squamous cell carcinoma · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q08AI8-F1 | alphafold | PREDICTED | 84.35 | — |
Amino-acid sequence (447 residues)
MPAPALPTSA MAVQVPLWHH YLQAIRSREA PRAQDFQRAE NVLLTVLERV HALDPRFIVD YSRGLEAFQF ALRSSEDPMD MEVPLWVDAE ALLIEEPEAT QPEDGLELCH LGVPREGAGL ERWTTEDTFT ASSEGDAKCR GHIVPSKVLC VLKDLLVAAI VHCKHHSLIA PGSLNAASLR EEQLHLSLLV SSGWRTISFH VVPVVRRKLG APALEGVQQM PGFPEGSLRR ILSQGVDLVP ASAQLWRTST DYLLTRLLGE LGSLQGHRLD SLSILDRVNH ESWRDSGQTD GLTFGHLKMV LLWASVLFLA PEDWAELQGA VYRLLVVLLC CLATRKLPHF LHPQRNLLQG SGLDLGAIYQ RVEGFASQPE AALRIHATHL GRSPPPRIGS GLKALLQLPA SDPTYWATAY FDVLLDKFQV FNIQDKDRIS AMQSIFQKTR TLGGEES
Explore Protein mab-21-like 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets